HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
The Week

'A rising tide scenario': Why other Big Pharmas could follow Lilly into psychedelics

After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.

By FierceBiotech · Jul 20, 2026 · via FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Novo, Alvotech face continued FDA scrutiny at plants tied to recent FDA rejections
From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufac…
Jul 20, 2026
States Cement 12-Month Medicaid Postpartum Coverage Option
The WeekBriefing
States Cement 12-Month Medicaid Postpartum Coverage Option
CMS and state actions under the American Rescue Plan Act and later legislation have made yearlong postpartum c…
Jul 20, 2026
Opinion: It's time to treat pandemics as threats to national security
The WeekSTAT News ↗
Opinion: It's time to treat pandemics as threats to national security
"Pandemics should be viewed and combated as threats to national security," write David Blumenthal and James A.…
Jul 20, 2026